Cell-cell adhesion genes CTNNA2 and CTNNA3 are tumour suppressors frequently mutated in laryngeal carcinomas

Nature Communications

Volumn 4, Issue , 2013, Pages

  Fanjul Fernández, Miriam ^a   Quesada, Víctor ^a   Cabanillas, Rubén ^b   Cadiñanos, Juan ^b   Fontanil, Tania ^a   Obaya, Álvaro ^a   Ramsay, Andrew J ^a   Llorente, José L ^c   Astudillo, Aurora ^c   Cal, Santiago ^a   López Otín, Carlos ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b Radiation Oncology Department   (Spain)

^c DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CATENIN; BETA CATENIN; CATENIN ALPHA 2; CATENIN ALPHA 3; UNCLASSIFIED DRUG;

CANCER; GENE EXPRESSION; MORBIDITY; MORTALITY; MUTATION; TUMOR;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; EXOME; FEMALE; GENE SEQUENCE; HUMAN; HUMAN TISSUE; LARYNX CARCINOMA; MALE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR RECURRENCE;

ALPHA CATENIN; AMINO ACID SEQUENCE; CARCINOMA, SQUAMOUS CELL; CELL ADHESION; CELL MOVEMENT; EXOME; GENE EXPRESSION; HUMANS; LARYNGEAL NEOPLASMS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM INVASIVENESS; PROGNOSIS; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL;

EID: 84885447107     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3531     Document Type: Article

References (30)

1. Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA. Cancer J. Clin. 55, 74-108 (2005).
2. Forastiere, A., Koch, W., Trotti, A. & Sidransky, D. Head and neck cancer. N. Engl. J. Med. 345, 1890-1900 (2001). (Pubitemid 33716564)
3. Agrawal, N. et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333, 1154-1157 (2011).
4. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157-1160 (2011).
5. Hunter, K. D., Parkinson, E. K. & Harrison, P. R. Profiling early head and neck cancer. Nat. Rev. Cancer 5, 127-135 (2005). (Pubitemid 40220338)
6. Belbin, T. J. et al. Site-specific molecular signatures predict aggressive disease in HNSCC. Head Neck Pathol. 2, 243-256 (2008).
7. Pleasance, E. D. et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463, 184-190 (2010).
8. Puente, X. S. et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101-105 (2011).
9. Quesada, V. et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 44, 47-52 (2012).
10. Ramsay, A. J. et al. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat. Genet. 45, 526-530 (2013).
11. Park, C., Falls, W., Finger, J. H., Longo-Guess, C. M. & Ackerman, S. L. Deletion in Catna2, encoding alpha N-catenin, causes cerebellar and hippocampal lamination defects and impaired startle modulation. Nat. Genet. 31, 279-284 (2002).
12. Janssens, B. et al. alphaT-catenin: a novel tissue-specific beta-catenin-binding protein mediating strong cell-cell adhesion. J. Cell Sci. 114, 3177-3188 (2001). (Pubitemid 32910472)
13. Forbes, S. A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-D950 (2011).
14. Liu, P. et al. Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis 33, 1270-1276 (2012).
15. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
16. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
17. Abe, K., Chisaka, O., Van Roy, F. & Takeichi, M. Stability of dendritic spines and synaptic contacts is controlled by alpha N-catenin. Nat. Neurosci. 7, 357-363 (2004). (Pubitemid 38429175)
18. Li, J. et al. Loss of alphaT-catenin alters the hybrid adhering junctions in the heart and leads to dilated cardiomyopathy and ventricular arrhythmia following acute ischemia. J. Cell Sci. 125, 1058-1067 (2012).
19. Polakis, P. Drugging Wnt signalling in cancer. EMBO J. 31, 2737-2746 (2012).
20. Clevers, H. & Nusse, R. Wnt/beta-catenin signaling and disease. Cell 149, 1192-1205 (2012).
21. Fang, D. et al. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J. Biol. Chem. 282, 11221-11229 (2007).
22. Arce, L., Yokoyama, N. N. & Waterman, M. L. Diversity of LEF/TCF action in development and disease. Oncogene 25, 7492-7504 (2006). (Pubitemid 44885748)
23. Killela, P. J. et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl Acad. Sci. USA 110, 6021-6026 (2013).
24. Canel, M., Serrels, A., Frame, M. C. & Brunton, V. G. E-cadherin-integrin crosstalk in cancer invasion and metastasis. J. Cell Sci. 126, 393-401 (2013).
25. Smartt, H. J. et al. beta-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells. Gut 61, 1306-1314 (2012).
26. Satow, R. et al. beta-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells. Gastroenterology 142, 572-581 (2012).
27. Bentley, D. R. et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456, 53-59 (2008).
28. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
29. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
30. Druley, T. E. et al. Quantification of rare allelic variants from pooled genomic DNA. Nat. Methods 6, 263-265 (2009).